Burkhard Bechinger

Professor

University of Strasbourg
Country flagFrance

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

The recently developed mRNA‐based coronavirus SARS‐CoV‐2 vaccines highlighted the great therapeutic potential of the mRNA technology. Although the lipid nanoparticles used for the delivery of the mRNA are very efficient, they showed, in some cases, the induction of side effects as well as the production of antibodies directed against particle components. Thus, the development of alternative delivery systems is of great interest in the pursuit of more effective mRNA treatments. In the present work, we evaluated the mRNA transfection capacities of a series of cationic histidine‐rich amphipathic peptides derived from LAH4. We found that while the LAH4‐A1 peptide was an efficient carrier for mRNA, its activity was highly serum sensitive. Interestingly, modification of this cell penetrating peptide at the N‐terminus with two tyrosines or with salicylic acid allowed to confer serum resistance to the carrier.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Francisco Ramos-Martín

Maître de Conférences (Associate Professor)

Université de Picardie Jules Verne

FRANCE
View details

Silvio Osella

associate professor

-

POLAND
View details

Antoine Kichler

University of Strasbourg

FRANCE
View details

Izabella Brand

-

GERMANY
View details

Dennis Wilkens Juhl

Aarhus University

DENMARK
View details

Nicola D'Amelio

professor

Université de Picardie Jules Verne

FRANCE
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.